EU No-Deal Still Haunts UK Medtechs As Brexit Remains On A Knife Edge
Executive Summary
The UK is the middle of a week of Brexit votes in Parliament, but confusion for medtechs and the wider industrial community has not been quelled at all, regardless of two days of voting already, and a third to come today.
You may also be interested in...
EU No-Deal Scenario Looms Still, But MHRA’s Reg Oversight Of UK Medtech On Hold
UK parliament’s indecision over how – or if – to enact Brexit saw the planned March 29 withdrawal deadline come and go. The default positions of the inter-ministerial Office for Lifesciences (OLS) and health-care products regulator (MHRA) are still to prepare for a no-deal exit from the EU.
DTx And Drug Deal Sees Closed Loop Medicine And Teva Team Up On Precision Care
Medicines are still typically prescribed based on average effects in a population and rarely dose-optimized for the individual, says Closed Loop Medicine. The company sees a new strategic partnership with Teva UK as another step in advancing personalized medicine.
Swiss-EU Standoff Set To End? Medtechs Eye MRA Action
Negotiations aimed at renewing the close trading relationship and barrier-free mutual market access between Switzerland and the EU got underway on 19 March. Swiss medtech companies welcomed the move, stressing the need for the defunct mutual recognition agreement to be updated.